

Resource Summary Report

Generated by [dkNET](#) on Aug 3, 2026

Purified anti-human CD3

RRID:AB_314055

Type: Antibody

Proper Citation

BioLegend Cat# 300401, RRID:AB_314055

Antibody Information

URL: http://antibodyregistry.org/AB_314055

Proper Citation: BioLegend Cat# 300401, RRID:AB_314055

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®, IHC-F, IP, Activ, WB

Antibody Name: Purified anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_314055

Vendor: BioLegend

Catalog Number: 300401

Alternative Catalog Numbers: 300402

Record Creation Time: 20250819T233909+0000

Record Last Update: 20250820T060006+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD3.

No alerts have been found for Purified anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Chen Q, et al. (2025) Systems-level immunomonitoring in children with solid tumors to enable precision medicine. *Cell*, 188(5), 1425.

Tan Z, et al. (2025) Immune development differs between preterm newborns fed mothers' own milk and donor milk. *iScience*, 28(7), 112918.

Sun J, et al. (2025) Blocking WNT7A Enhances MHC-I Antigen Presentation and Enhances the Effectiveness of Immune Checkpoint Blockade Therapy. *Cancer immunology research*, 13(3), 400.

Rashleigh L, et al. (2025) Antibody-like recognition of a ?? T cell receptor toward a foreign antigen. *Structure (London, England : 1993)*.

Maas RR, et al. (2023) The local microenvironment drives activation of neutrophils in human brain tumors. *Cell*, 186(21), 4546.

McCubbrey AL, et al. (2022) Polyamine import and accumulation causes immunomodulation in macrophages engulfing apoptotic cells. *Cell reports*, 38(2), 110222.

Hartmann FJ, et al. (2019) Comprehensive Immune Monitoring of Clinical Trials to Advance Human Immunotherapy. *Cell reports*, 28(3), 819.